PTO- 1478 |
Approved for use through 09/30/2021. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97027082 |
Filing Date: 09/14/2021 |
Input Field |
Entered |
TEAS Plus | YES |
---|---|
MARK INFORMATION | |
*MARK | Tuxarin |
*STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | Tuxarin |
*MARK STATEMENT | The mark consists of standard characters, without claim to any particular font style, size, or color. |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | MainPointe Pharmaceuticals, LLC |
*MAILING ADDRESS | 2604 River Green Circle |
*CITY | Louisville |
*STATE (Required for U.S. applicants) |
Kentucky |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
40206 |
PHONE | 502-709-7544 |
*EMAIL ADDRESS | XXXX |
WEBSITE ADDRESS | www.mainpointepharmaceuticals.com |
LEGAL ENTITY INFORMATION | |
*TYPE | LIMITED LIABILITY COMPANY |
* STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY WHERE LEGALLY ORGANIZED | Kentucky |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
*INTERNATIONAL CLASS | 005 |
*IDENTIFICATION | Pharmaceutical preparations for the treatment of coughs and colds; Pharmaceutical preparations for treating allergic rhinitis; Pharmaceutical preparations for treating allergies |
*FILING BASIS | SECTION 1(a) |
FIRST USE ANYWHERE DATE | At least as early as 10/01/2018 |
FIRST USE IN COMMERCE DATE | At least as early as 10/01/2018 |
SPECIMEN FILE NAME(S) |
\\TICRS\EXPORT18\IMAGEOUT 18\970\270\97027082\xml1 \ FTK0003.JPG |
SPECIMEN DESCRIPTION | Screenshot of the Tuxarin product page from the MainPointe website |
WEBPAGE URL | www.mainpointepharmaceuticals.com |
WEBPAGE DATE OF ACCESS | 08/25/2021 |
ADDITIONAL STATEMENTS INFORMATION | |
*TRANSLATION (if applicable) |
|
*TRANSLITERATION (if applicable) |
|
*CLAIMED PRIOR REGISTRATION (if applicable) |
|
*CONSENT (NAME/LIKENESS) (if applicable) |
|
*CONCURRENT USE CLAIM (if applicable) |
|
CORRESPONDENCE INFORMATION | |
NAME | MainPointe Pharmaceuticals, LLC |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | ip@mainpointepharmaceuticals.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | NOT PROVIDED |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Plus |
NUMBER OF CLASSES | 1 |
APPLICATION FOR REGISTRATION PER CLASS | 250 |
*TOTAL FEES DUE | 250 |
*TOTAL FEES PAID | 250 |
SIGNATURE INFORMATION | |
* SIGNATURE | /Frank L. Yetter/ |
* SIGNATORY'S NAME | Frank L. Yetter |
* SIGNATORY'S POSITION | Vice President - Manager |
SIGNATORY'S PHONE NUMBER | 502-709-7544 |
* DATE SIGNED | 09/14/2021 |
SIGNATURE METHOD | Signed directly within the form |
PTO- 1478 |
Approved for use through 09/30/2021. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97027082 |
Filing Date: 09/14/2021 |
The applicant's current Correspondence Information: |
MainPointe Pharmaceuticals, LLC |
PRIMARY EMAIL FOR CORRESPONDENCE: ip@mainpointepharmaceuticals.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |
|
|